Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis
Aim. To evaluate the efficacy and safety of the Russian biosimilar infliximab in patients with ulcerative colitis (UC). Materials and methods. This is a retrospective study of stable patients with UC, who are followed up at the department of bowel pathology of Loginov Moscow Clinical Scientific C...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2025-01-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/646287/193077 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850192755571032064 |
|---|---|
| author | Maria I. Timanovskaia Oleg V. Knyzev Asfold I. Parfenov |
| author_facet | Maria I. Timanovskaia Oleg V. Knyzev Asfold I. Parfenov |
| author_sort | Maria I. Timanovskaia |
| collection | DOAJ |
| description | Aim. To evaluate the efficacy and safety of the Russian biosimilar infliximab in patients with ulcerative colitis (UC).
Materials and methods. This is a retrospective study of stable patients with UC, who are followed up at the department of bowel pathology of Loginov Moscow Clinical Scientific Center and who underwent a non-medical switch from the original infliximab to its Russian biosimilar. The primary outcome is treatment continuation for 16 weeks after the switch. Secondary outcomes include the rate of loss of response, adverse events, and immunogenicity during the first 12 months after the switch.
Results. There was no significant difference in infliximab continuation between the biosimilar, switch and control groups. While the alternation group had the highest rate of loss of response and adverse events.
Conclusion. Non-medical switching from the original infliximab to its Russian biosimilar, as well as therapy with a biosimilar under one trade name, demonstrates similar clinical results compared to continuing to take the original molecule for the treatment of UC. The obtained data confirm the safety and efficacy of non-medical switching to infliximab in patients with UC. |
| format | Article |
| id | doaj-art-6b192cfc19e04997a422f96b32e448e4 |
| institution | OA Journals |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| publishDate | 2025-01-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj-art-6b192cfc19e04997a422f96b32e448e42025-08-20T02:14:26Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422025-01-0197214514810.26442/00403660.2025.02.20318478664Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitisMaria I. Timanovskaia0https://orcid.org/0000-0002-7937-2346Oleg V. Knyzev1https://orcid.org/0000-0001-7250-0977Asfold I. Parfenov2https://orcid.org/0000-0002-9782-4860Loginov Moscow Clinical Scientific CenterLoginov Moscow Clinical Scientific CenterLoginov Moscow Clinical Scientific CenterAim. To evaluate the efficacy and safety of the Russian biosimilar infliximab in patients with ulcerative colitis (UC). Materials and methods. This is a retrospective study of stable patients with UC, who are followed up at the department of bowel pathology of Loginov Moscow Clinical Scientific Center and who underwent a non-medical switch from the original infliximab to its Russian biosimilar. The primary outcome is treatment continuation for 16 weeks after the switch. Secondary outcomes include the rate of loss of response, adverse events, and immunogenicity during the first 12 months after the switch. Results. There was no significant difference in infliximab continuation between the biosimilar, switch and control groups. While the alternation group had the highest rate of loss of response and adverse events. Conclusion. Non-medical switching from the original infliximab to its Russian biosimilar, as well as therapy with a biosimilar under one trade name, demonstrates similar clinical results compared to continuing to take the original molecule for the treatment of UC. The obtained data confirm the safety and efficacy of non-medical switching to infliximab in patients with UC.https://ter-arkhiv.ru/0040-3660/article/viewFile/646287/193077ulcerative colitisbiosimilarinfliximab |
| spellingShingle | Maria I. Timanovskaia Oleg V. Knyzev Asfold I. Parfenov Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis Терапевтический архив ulcerative colitis biosimilar infliximab |
| title | Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis |
| title_full | Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis |
| title_fullStr | Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis |
| title_full_unstemmed | Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis |
| title_short | Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis |
| title_sort | results of non medical switching from original infliximab to its russian biosimilar in patients with ulcerative colitis |
| topic | ulcerative colitis biosimilar infliximab |
| url | https://ter-arkhiv.ru/0040-3660/article/viewFile/646287/193077 |
| work_keys_str_mv | AT mariaitimanovskaia resultsofnonmedicalswitchingfromoriginalinfliximabtoitsrussianbiosimilarinpatientswithulcerativecolitis AT olegvknyzev resultsofnonmedicalswitchingfromoriginalinfliximabtoitsrussianbiosimilarinpatientswithulcerativecolitis AT asfoldiparfenov resultsofnonmedicalswitchingfromoriginalinfliximabtoitsrussianbiosimilarinpatientswithulcerativecolitis |